This has been demonstrated to be the case in a closely related uterine cancer type – serous carcinomas (usually TP53-mutated with a high degree of CNA), where ERBB2 amplification/copy number gain contributes to tumor growth which can be targeted to improve patient survival clinically [23]. This evidence concerns the gene ERBB2 and serous adenocarcinoma.